Enjoy complimentary customisation on priority with our Enterprise License!
Get our updated market research report on the Human Growth Hormone Market in the US 2018-2022
Human growth hormone, also known as somatotropin, is a peptide with 191 amino acids and 2 sulfhydryl bridges. It is produced by the anterior pituitary, and it is required to attain normal size for children and adolescents. It also has major effects on lipid and carbohydrate metabolism of an individual. The effects of human growth hormone are mainly mediated by IGF-1 and IGF-2. There are two forms of recombinant human growth hormone approved in the market: Somatropin and Somatrem. Somatropin has 191 amino acids and Somatrem contains 192 amino acids. Growth hormone deficiency can occur either due to a damage to the pituitary or the hypothalamus gland, or can also be acquired genetically. Some of the signs of growth hormone deficiency are adiposity, short stature, and hypoglycemia. According to the human growth hormone market analysis, Technavio's analysts predict that this market in the US to grow at a CAGR of 3.86 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the human growth hormone market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the various human growth hormone drugs available in the US for the treatment of growth hormone deficiency.
Technavio's report, the human growth hormone market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the human growth hormone market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Vendors
• F. Hoffmann-La Roche
• Merck Serono
• Novo Nordisk
• Pfizer
Other Prominent Vendors
• Eli Lilly
• Teva Pharmaceutical
• Novartis
• Ipsen
Market Driver
• Demand for Human Growth Hormone
• For a full, detailed list, view our report
Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report
Market Trend
• Growing Focus on Needle-free Drug Delivery Devices
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Technavio also provides customized reports based on the specific requirements of our clients.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Human Growth Hormone: An Overview
05.1 About Human Growth Hormone
05.2 Pharmacological Action of Human Growth Hormone
05.3 Therapeutic Uses of Human Growth Hormone: US FDA
05.4 Growth Hormone Deficiency
05.4.1 Childhood-onset growth hormone deficiency
05.4.2 Adult-onset growth hormone deficiency
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Trends and their Impact
15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Market Share Analysis 2014
15.2.1 Merck Serono
15.2.2 Pfizer
15.2.3 Novo Nordisk
15.2.4 F. Hoffmann-La Roche
15.3 Other Prominent Vendors
16. Key Vendor Analysis
16.1 F. Hoffmann-La Roche Ltd.
16.1.1 Key Facts
16.1.2 Business Overview
16.1.3 Business Segmentation
16.1.4 Business Segmentation by Revenue 2012 and 2013
16.1.5 Sales by Geography
16.1.6 Business Strategy
16.1.7 Key Information
16.1.8 SWOT Analysis
16.2 Merck Serono
16.2.1 Key Facts
16.2.2 Business Overview
16.2.3 Geographical Segmentation by Revenue 2013
16.2.4 Business Strategy
16.2.5 Recent Developments
16.2.6 SWOT Analysis
16.3 Novo Nordisk A/S
16.3.1 Key Facts
16.3.2 Business Overview
16.3.3 Business Segmentation by Revenue 2013
16.3.4 Business Segmentation by Revenue 2012 and 2013
16.3.5 Sales by Geography
16.3.6 Business Strategy
16.3.7 Key Information
16.3.8 SWOT Analysis
16.4 Pfizer
16.4.1 Key Facts
16.4.2 Business Overview
16.4.3 Business Segmentation by Revenue 2013
16.4.4 Business Segmentation by Revenue 2012 and 2013
16.4.5 Geographical Segmentation by Revenue
16.4.6 Business Strategy
16.4.7 Key Developments
16.4.8 SWOT Analysis
17. Other Reports in this Series
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.